CD274 and non-small cell lung carcinoma: So far, tissue programmed cell death ligand 1 (PD-L1) expression has been validated as a predictive biomarker of ICI treatment outcomes, including anti-PD-1/PD-L1 therapy, in NSCLC [28,29].